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OBJECTIVES: Drug safety problems can lead to hospital admission. In Brazil, the prevalence of hospitalization
due to adverse drug events is unknown. This study aims to estimate the prevalence of hospitalization due to
adverse drug events and to identify the drugs, the adverse drug events, and the risk factors associated with
hospital admissions.
METHOD: A cross-sectional study was performed in the internal medicine ward of a teaching hospital in Sa˜o
Paulo State, Brazil, from August to December 2008. All patients aged $18 years with a length of stay$24 hours
were interviewed about the drugs used prior to hospital admission and their symptoms/complaints/causes of
hospitalization.
RESULTS: In total, 248 patients were considered eligible. The prevalence of hospitalization due to potential
adverse drug events in the ward was 46.4%. Overprescribed drugs and those indicated for prophylactic
treatments were frequently associated with possible adverse drug events. Frequently reported symptoms were
breathlessness (15.2%), fatigue (12.3%), and chest pain (9.0%). Polypharmacy was a risk factor for the
occurrence of possible adverse drug events.
CONCLUSION: Possible adverse drug events led to hospitalization in a high-complexity hospital, mainly in
polymedicated patients. The clinical outcomes of adverse drug events are nonspecific, which delays treatment,
hinders causality analysis, and contributes to the underreporting of cases.
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& INTRODUCTION
Adverse drug events (ADEs) involve ‘‘harm caused by a
drug or the inappropriate use of a drug’’ (1). ADEs can
mimic diseases, decrease the confidence of patients in
doctors, and delay both diagnosis and treatment (2). These
events are responsible for up to 54% of hospital admissions
(3), and 1.5% of them are fatal (2). Moreover, ADEs can
increase the length of hospital stays by 2.9 days, raising
hospital costs (4).
Factors that predispose a patient to ADEs are age (5,6),
female gender (6), and polypharmacy (6,7). There is no
consensus regarding alcohol consumption as a risk factor
for the occurrence of an adverse drug reaction (8,9), which is
a negative clinical outcome related to an ADE.
In Brazil, pharmacovigilance is recent, and there have
been few studies assessing drug safety and ADE-related
hospital admissions. This study aims to estimate the number
of patients with symptoms consistent with a known ADE; to
assess the likelihood that a drug caused an ADE; and to
identify the drugs, the ADEs themselves, and the risk
factors associated with hospitalization.
& MATERIALS AND METHODS
A cross-sectional pilot study was performed in a general,
public state teaching hospital in Sa˜o Paulo State, Brazil, with
848 active beds.
All patients aged $18 years who agreed to participate by
providing written informed consent; who had taken at least
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one drug before hospital admission; and who were admitted
to the internal medicine ward (107 beds) from August 19 to
December 19, 2008, met the inclusion criteria and were
enrolled. The exclusion criteria were patients transferred
from another hospital or ward; those with prescheduled
surgery; those unable to communicate (intubated, in
isolation, or mentally disoriented); and those with a hospital
stay #24 hours, including patients in the emergency unit,
who cannot be interviewed, and certain internal medicine
patients who were admitted to the ward for rapid treatment
with drugs whose use is restricted to hospital wards.
Employing a validated form (10), the investigator inter-
viewed the subjects who met the inclusion criteria to collect
the data. The instrument was designed to have three
sections. The first section collected personal information
regarding the patient, such as the initials of the name and
sociodemographic characteristics (alcohol consumption,
smoking habits, gender, and age group [elderly or not
elderly]). This part also included data on patient hospital
registration and bed and the dates and times of hospital
admission and discharge. The second section addressed the
personal history of drug treatment to identify the drugs
administered prior to hospital admission and the com-
plaints/reasons for hospitalization. The third section com-
prised questions that allowed the analysis of causal
association by collecting data about the time relationship
between drug use and the adverse event, the response to
dechallenge (discontinuation of or decrease in dose), and
the response to rechallenge (drug re-administration) and
about competing causes of the ADEs (implying that the
complaint reported by a patient was not related to drug
use).
In addition, medical prescriptions brought by patients
were consulted with the aim of confirming the pharma-
cotherapy prescribed by the family doctor. When medical
prescriptions were not available but either patients or their
caregivers noted that they were able to reply to all points
raised on the form, without loss of information, medical
records were not consulted. This approach was adopted due
to a lack of information about the personal history of drug
treatment performed at home in these documents. In cases
in which the patients did not present their medical
prescriptions and could not remember the drugs taken at
home, medical records were consulted as a last source of
data on drugs administered.
To determine whether the complaints/reasons for hospi-
talization reported by patients were expected ADEs
(described in clinical trials) and to perform a causality
assessment, the drug information sheets approved by the
National Agency of Sanitary Surveillance (ANVISA) and
monographs, such as those in DRUGDEX (MICROMEDEXH
database), were consulted.
For the causality assessment, the algorithm of Naranjo
(11) was employed. Causal association was performed by a
pharmacist, based on the complaints reported by patients,
the drugs used prior the hospitalization (second section of
the instrument), and the questions raised in the algorithm of
Naranjo (11) (third section of the instrument). When a likely
connection between drug intake and the occurrence of a
negative outcome was found, the drugs related to the ADE
were classified according to the Anatomical Therapeutic
Chemical (ATC) Code.
Data obtained from the interviews and the likelihood of
ADE were expressed as frequencies and subjected to an
analysis of descriptive statistics. The chi-squared test was
applied to the dichotomous variables age (elderly or not
elderly), gender, ethanol consumption, and smoking habit
to reveal statistically significant differences between
patients who were possibly hospitalized due to an ADE
and those who were admitted for other reasons. Patients
aged $60 years were considered ‘‘elderly’’. Odds ratios
(ORs) were calculated to analyze the association between
dichotomous variables and the occurrence of ADEs. The
Mann-Whitney test was used to assess the statistical
significance of associations between the number of drugs
(continuous variable with nonparametric distribution) and
the risk of an ADE and between the length of stay
(independent variable) and an ADE related to hospitaliza-
tion. The intake of five or more drugs was considered
polypharmacy (12).
To control for potential confounding factors and to
determine independent associations between an ADE and
its risk factors, multivariate logistic regression analysis was
employed, with an ADE as the outcome and gender, age,
ethanol consumption, smoking habit, the number of drugs
used, and the length of stay as independent variables. In all
tests, significance was accepted when p,0.05.
& RESULTS
During the study period, 1,180 patients were admitted to
the internal medicine ward. Of these patients, 664 (56.3%)
met the exclusion criteria, and 260 (22.0%) could not be
interviewed. In total, 256 (21.7%) met the inclusion criteria.
Seven patients did not remember the drugs taken at home,
and this information was not found in medical records, and
one patient withdrew his consent during data collection, so
only 248 patients were considered eligible. Therefore, the
prevalence of hospital admission due to a potential ADE
was 46.4% (115/248).
Patients reported 178 ADEs. Six (3.4%) were classified as
definite, 54 (30.3%) as probable, and 118 (66.3%) as possible.
Frequently reported ADEs were breathlessness (15.2%),
fatigue (12.3%), chest pain (9.0%), abdominal pain (8.9%),
and hyperglycemia (5.6%).
By univariate analysis, ethanol consumption and poly-
pharmacy were detected as a protective factor and a risk
factor, respectively, for the occurrence of ADE (Table 1).
However, in the multivariate regression analysis, only
polypharmacy showed a significant influence on ADE
occurrence. Furthermore, no significant difference was
observed in the length of hospital stay for patients admitted
due to an ADE (Table 1).
The therapeutic classes of the 10 drugs frequently
associated with ADEs were cardiovascular, alimentary tract,
and metabolism and blood and blood-forming organs
(Table 2).
& DISCUSSION
The prevalence of severe ADEs that might lead to hospital
admission was found to be approximately one in two
patients who had taken at least one drug prior to
hospitalization. Severe ADEs are defined as causing
hospitalization, being fatal or life-threatening, or resulting
in significant changes in a patient’s treatment (presumably
thereby prolonging hospitalization) (13). Our findings
corroborate the data of a systematic review (3) and can be
used as an indicator of the need for a safety assessment of
ADE-related hospital admissions
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the pharmacotherapies prescribed at the primary and
secondary health care levels, for pharmacotherapeutic
follow-up of patients, and for the development of risk
minimization plans to allow the early recognition of drug-
related problems (DRPs) to avoid inappropriate prescrib-
ing/health care and to improve patient safety. Such
measures could contribute to the reduction of hospitaliza-
tion related to DRPs and hospital costs (3).
Most of the hospital admissions possibly arising from
ADEs that were detected in the present study were
associated with cardiovascular drugs. This finding was
expected because it was also observed by Kongkaew et al.
(7). Salicylates are often prescribed to patients with
hypertension and diabetes to avoid cardiovascular compli-
cations (14). However, acetylsalicylic acid has been asso-
ciated with hospital admissions arising from ADEs (5).
Therefore, patients who take cardiovascular and antithrom-
botic drugs should be included and prioritized in pharma-
ceutical care services to assess the safety of the prophylactic
treatment and to decrease the prevalence of hospitalizations
due to DRPs.
Omeprazole was the main drug responsible for hospita-
lizations related to symptoms that were consistent with a
known ADE. In Brazil, the prescription of and self-
medication with omeprazole are common among patients
treated with polypharmacy to prevent disorders of the
digestive tract. Therefore, the high frequency of omepra-
zole-related possible ADEs was expected due to its over-
prescription. However, this finding does not necessarily
imply a real causal relationship because the clinical
manifestations of the possible ADEs reported by patients
may have been symptoms of undertreated disorders, such
as ulcer and reflux.
Clinical manifestations of ADEs were nonspecific, hinder-
ing their detection and leading to overestimation in the
causality assessment. Overestimates most likely occur
because few professionals are qualified to perform activities
related to post-commercialization surveillance, given that it
is only a recent practice in Brazil. This surveillance began in
2001 with the project of Sentry Hospitals. The main aim of
the network of Sentry Hospitals is to establish a culture of
ADE reporting to quantitatively increase the amount of
information regarding DRPs. In 2013, the Health Ministry
established the National Program of Patient Safety (15),
which may contribute to the assessment of ADE causality
because this program encourages the discussion of risk
management among the members of multidisciplinary
teams involved in health care, improving the quality of
information.
The algorithm of Naranjo also limits the assessment of the
likelihood of ADEs because this instrument was developed
for controlled clinical trials whose risk management and
health care are different from those of the participants
enrolled in the present study. Thus, the algorithm includes
several clinical practices that are not frequently conducted
(for example, laboratory tests to check the plasma concen-
trations of most drugs are not performed, reexposure of the
patient to the drugs is rarely conducted, and the adminis-
tration of placebo is considered to be an ethical issue and is
strongly discouraged). Thus, withdrawal of the drug with a
consequent improvement of the patient is the only para-
meter used to assess causality when other conditions do not
explain a patient’s symptoms (16).
Moreover, it is important to stress that the strength of
causal association depends on the quantity and quality of
information collected, which should be revised as more
information becomes available (1). However, because the
Table 1 - Frequency of ADEs identified according to potential risk factors in groups of patients admitted to the internal
medicine ward (n = 248).
Variable ADE Univariate analysis Logistic regression
No Yes OR raw (95%) CI OR adj. (95% CI)
Gender
Female 74 (49.3) 76 (50.7) (a)1.00 (0.9-2.6) 1.00 (0.77-2.32)
Male 59 (60.2) 39 (39.8) 1.60 1.34
Age
Not elderly 84 (56.0) 66 (44.0) 1.00 (0.8-2.1) 1.00 (0.66-1.93)
Elderly 49 (50.0) 49 (50.0) 1.30 1.13
Ethanol consumption
No 108 (50.7) 105 (49.3) 1.00 (0.2-0.9)* 1.00 (0.17-1.02)
Yes 25 (71.4) 10 (28.6) 0.40 0.42
Smoking habit
No 116 (54.2) 98 (45.8) 1.00 (0.6-2.4) 1.00 (0.91-4.73)
Yes 17 (50.0) 17 (50.0) 1.20 2.07
Number of drugs (p:U)
Median 4 5 0.006+ 1.14 (1.03-1.26) **
inimum 1 1
Maximum 13 14
Length of stay (days)
Median 8 8 0.572 1.00 (0.98-1.02)
Minimum 1 1
Maximum 147 81
OR raw: Odds ratio, 95% CI = 95% confidence interval;
OR adj.: Adjusted odds ratio; 95% CI = 95% confidence interval.
*Significant: patients who reported ethanol consumption were less likely to experience an ADE (chi-squared: p,0.05).
+ Significant: a higher number of drugs used increased the occurrence of an ADE (chi-squared: p,0.05).
**Significant: the odds of an ADE increased by 14% when one more drug was administered.
(a) OR = 1.00 indicates the group used as a reference.
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data collection depended on the memory of the subjects
enrolled in the study and given the lack of information
regarding pharmacotherapeutics taken at home (including
adherence and self-medication) and the difficulty in
discussing the cases with the family physicians of the
patients (they were not linked to the institution), the
assessment of ADE likelihood was impaired. Nevertheless,
the report of any suspicion of an ADE is encouraged by
ANVISA. Therefore, even when the Naranjo algorithm
indicated a weak likelihood (possible) that a drug was
associated with the complaints reported, we included this
information in our findings.
Polypharmacy was the only risk factor for the occurrence
of ADEs. In fact, each drug added to a treatment may
increase the probability of ADE development by 14%.
Although we did not observe the occurrence of ADEs
arising from polypharmacy to be higher in elderly people,
particular care should be taken with this age group because
they are more susceptible to the development of ADEs (17).
Varallo et al. (18) demonstrated that the use of several drugs
contributed to hospital admission because of DRPs.
Furthermore, polypharmacy increases the chance of
prescribing drug interactions. Therefore, simpler pharma-
cotherapy should be considered by physicians to improve
the clinical outcome of the patient, to decrease the rate of
noncompliance with treatment due to complex dosing
schedules, to contribute to safer pharmacotherapy, and to
avoid the misuse and prescription of unnecessary drugs.
Most of the patients reported moderate alcohol intake and
use of cardiovascular drugs. Kloner et al. (19) observed that
light-to-moderate intake of alcohol can have beneficial
effects on the circulatory system. This finding may explain
the lower risk of hospitalization due to an ADE in patients
who consumed ethanol, according to the univariate analy-
sis.
Limitations of the study
The prevalence of hospitalization arising from ADEs may
have been overestimated due to 1) the use of a convenience
sample; 2) the method of data collection (depending on the
memory of the patients and/or their caregivers); 3) a lack of
high-quality clinical information (the physicians responsible
for prescriptions did not work at the institution, and the
patients were poor responders); and 4) the use of the
algorithm of Naranjo, which was developed to analyze the
safety of drugs in controlled clinical trials. Therefore, the
issues addressed by this tool (algorithm) could not all be
investigated because of the methodology of the present study.
However, despite its limitations, the present study has
scientific relevance, as it portrays a problem that is little
known in Brazil and highlights possible difficulties related
to the post-marketing surveillance of drugs and causality
analyses of ADEs. Moreover, the study demonstrates the
need to develop tools which can improve causality assess-
ment of the causal association between the use of drugs and
the development of adverse events and to validate tools
with higher sensitivity to identify ADEs. It is also necessary
to provide continuing education to qualify health profes-
sionals to perform pharmacovigilance activities. Moreover,
this study fosters discussion regarding the assessment of
Table 2 - Frequency of the 10 drugs most commonly taken by patients prior to admission to the internal medicine ward,
as reported at hospital admission, along with their ATC codes, the ADEs identified, and an assessment of causality using
the Naranjo algorithm.
Drug N ATC code* ADE related to hospital admission
Causality
assessment
Omeprazole 23 A Fatigue (3), abdominal pain (1), chest pain (2), cough (4), diarrhea (1), edema (1),
anemia (1)
Probable
Abdominal pain (5), bronchospasm (4), fatigue (4), chest pain (2), back pain (2),
vomiting (1), edema (1), diarrhea (1), hepatotoxicity (1), leg pain (1), fever (1),
tachycardia (1)
Possible
Captopril 20 C Cough (3), bronchospasm (1), tachycardia (1) Probable
Bronchospasm (7), angina (6), diarrhea (3), cough (1), tachycardia (1), gastrointestinal
ulcer (1), fever (1), abdominal pain (1), vomiting (1), hypoglycemia (1), somnolence (1),
hypotension (1)
Possible
Insulin 20 A Insulin resistance (3), bronchospasm (2), chest pain (1), diarrhea (1), anemia (1),
edema (1)
Probable
Insulin resistance (5), bronchospasm (3), chest pain (4), diarrhea (1), hypoglycemia (1), Possible
Acetylsalicylic acid 17 B Bronchospasm (3), angina (1), Probable
Bronchospasm (11), angina (2), hypertension (1), gastrointestinal ulcer (1) Possible
Furosemide 14 C Abdominal pain (2), diarrhea (1), anemia (1), fever (1) Probable
Abdominal pain (2), dizziness (3), diarrhea (2), nausea (1), erythema (1), hyperglycemia (1),
fever (1)
Possible
Propranolol 10 C Fatigue (1), bronchospasm (2), angina (1), diarrhea (1), pruritus (1) Probable
Fatigue (5), bronchospasm (3), angina (1), vomiting (1), gastrointestinal disorder (1) Possible
Simvastatin 10 C Angina (2), dizziness (2), abdominal pain (1) Probable
Angina (2), dizziness (2), proteinuria (2), fatigue (2), abdominal pain (1), constipation (1) Possible
Carvedilol 8 C Bronchospasm (1), edema (1), cough (1), syncope (1), Probable
Bronchospasm (3), edema (2), fatigue (2), angina (1), erythema (1) Possible
Digoxin 8 C Poisoning by glycoside cardiac (1), Definite
Poisoning by glycoside cardiac (1), dizziness (1), abdominal pain (1), headache (1) Probable
Fatigue (2), dizziness (1), Possible
Enalapril 7 C Dizziness (1), paresthesia (1) Definite
Dizziness (1), hyperglycemia (2), fatigue (1), anemia (1) Probable
Myalgia (1), cough (1) Possible
*ATC codes: A = alimentary tract and metabolism; B = blood and blood-forming organs; C = cardiovascular system.
ADE-related hospital admissions
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health care services provided at the primary and secondary
levels to improve patient safety and the awareness of drug
takers regarding their pharmacotherapy and health condi-
tions.
Finally, the early detection of ADEs with a high degree of
fidelity is of significant interest to health authorities because
post-marketing surveillance provides warnings regarding
drug safety problems and may trigger actions to reduce the
negative outcomes associated with pharmacotherapies.
Therefore, pharmacovigilance activities contribute to the
rational use of drugs and thus may decrease ADE-related
hospital admissions.
Approximately one in two community-dwelling drug
takers may be hospitalized due to an ADE. Polypharmacy is
a risk factor for the occurrence of ADEs. Data suggest the
need to assess the risk/benefit of the prophylactic use of
omeprazole and acetylsalicylic acid because these drugs are
overprescribed and frequently associated with hospital
admissions and negative outcomes. The clinical manifesta-
tions of ADEs are nonspecific, which delays treatment,
hinders causality analysis, and contributes to the under-
reporting of cases.
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